Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies: Independent 2023 Conference/Congress Coverage

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.50
Insight on Key New Data From the 2023 ESMO Annual Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Slides: CCO 2023 Global Conference Coverage: Gynecologic Cancer Updates

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

1.00
2022 ESGO Congress: Experts Discuss HRD Testing, PARP Inhibitors in Recurrent Ovarian Cancer, and QoL in Nonepithelial Ovarian Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
CCO 2022 Global Conference Coverage: Gynecologic Cancer Updates

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
CCO 2021 Global Conference Coverage: Gynecologic Cancer Updates

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Current Status and European Perspective on the Application of Actionable Biomarkers for Ovarian and Endometrial Cancers

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Global Perspectives on the Implications of Key New Data With Targeted Therapy Combinations in Solid Tumors From ASCO 2021

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Key Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence

Content Format:

Multimedia

Credit Type:

AMA

Credits:

0.75
ExpressPointsKey Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Should PARP Inhibitors be Used Alone or in Combinations for Ovarian Cancer? The Influence of Patient and Disease Factors

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Cancer Conversations™: Experts Discuss the New Immunotherapy Paradigm in Endometrial Cancer

Content Format:

Multimedia

Credit Type:

--

Credits:

--
ExpressPointsCancer Conversations™: Experts Discuss the New Immunotherapy Paradigm in Endometrial Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Cancer Conversations™: Experts Discuss the New Immunotherapy Paradigm in Endometrial Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Biomarkers in Ovarian Cancer: Expert Discussion of Options for First-line Maintenance Therapy

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Biomarkers in Ovarian Cancer: Expert Discussion of Options for First-line Maintenance Therapy

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
An Expert Roundtable Exploring Recent Data in Ovarian Cancer and its Impact on Patient Care

Content Format:

Video

Credit Type:

--

Credits:

--
Optimizing the Use of PARP Inhibitors for the Treatment of Patients With Ovarian Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--